open.michigan

Author(s): Sandro Cinti, M.D., 2009

License: Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution – Share Alike 3.0 License**: http://creativecommons.org/licenses/by-sa/3.0/

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact **open.michigan@umich.edu** with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit http://open.umich.edu/education/about/terms-of-use.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.





Citation Key

for more information see: http://open.umich.edu/wiki/CitationPolicy

Use + Share + Adapt		
{ Content the copyright holder, author, or law permits you to use, share and adapt. }		
PD-GOV	Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)	
Ø PD-EXP	Public Domain – Expired: Works that are no longer protected due to an expired copyright term.	
Ø PD-SELF	Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.	
(0) 2880	Creative Commons – Zero Waiver	
(c)) ar	Creative Commons – Attribution License	
(C) 87-5A	Creative Commons – Attribution Share Alike License	
(C) 87-NC	Creative Commons – Attribution Noncommercial License	
(0) BY-NC-SA	Creative Commons – Attribution Noncommercial Share Alike License	
GNU-FDL	GNU – Free Documentation License	

Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }

Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ

{ Content Open.Michigan has used under a Fair Use determination. }



Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ

Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should do your own independent analysis to determine whether or not your use will be Fair.

Biopreparedness

M1 Infectious Diseases Sequence Sandro Cinti



Spring 2009



What is Bioterrorism?

 Bioterrorism is the malevolent use of viruses, bacteria, fungi or toxins to produce death or disease in humans, animals or plants.

Any Examples of Bioterrorism?

- 1360 Plague victims' bodies thrown over besieged city's walls
- 1763 Europeans give smallpox infected blankets to Native Americans
- 1984 Bhagwan Shree Rajneesh contaminates food with Salmonella to win election
- 1994 Shoko Assahara group attack Tokyo subway with sarin gas
- 2001 Anthrax



Admin-2000, wikimedia commons

The 1979 Sverdlovsk Anthrax Outbreak





See: http://www.semp.us/publications/biot_reader.php?BiotID=324

Why use biological weapons?

Why Use Biological Weapons?

- Cheap-800 X less than nucs
- Easy to acquire
 - Dual use
 - Web-based information
- High Fatality
 - 100 kg anthrax could kill 3 million (OTA report, 1993)
- High Panic factor

What makes a good bioweapon?

HHS AND USDA SELECT AGENTS AND TOXINS 7 CFR Part 331, 9 CFR Part 121, and 42 CFR Part 73

HHS SELECT AGENTS AND TOXINS

Abrin Carcopithecine (harpesvirus 1 (Herpes II virus) Cocoldioides posadiasi/ Constants Crimean-Congo haemonthagic lever virus Diacetosyscirpenol Ebola virus Lassa fever virus Merburg virus Monkeypox Virus Reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments (Reconstructed 1918 Influenza virus) Ricin Rickeltale prowabeki Rickettaia rickettai Sanitourn Shipa-like ribosome inactivaling proteins South American Haemonthesic Fever viruses Fiexal Guanantio 20101 Machupo Table. Terrodolizain Tick-borne encephalite complex (flavi) viruses Central European Tick-borne encephalitis Far Eastern Tick-borne encephalitis Kyasana Poresi disease Omsk Hemonfragic Fever Russian Spring and Summer encephalitis Variola major veus (Stealpox veus) and Variola minor virus (Alastrim) Versitive permit

OVERLAP SELECT AGENTS AND TOXINS Beoflus antivace Botulnum neurotrains Botulinum neurolaxin producing species of Closhidium Brucella abortus Brucella mellenssi Brucelta suis-Burkholderia mallel (formerty Pseudomonas maller) Burkholden's pseudomater (formerly Pseudomonae pseudomater) Closhidium perhingenis epsilon toxin Cooridioides anométic Covieite burneti Eastern Equine Encephalitis virus Francisella tularensis Hendra Unus Npah virus Rift Valley fever virus Shipatown Staphyhococcal emergionists T-2 tosin Venezuelan Equine Encephalitis virus

USDA SELECT AGENTS AND TOXING

African horse sickness virus African swine fever virus Akabane virtus Avian influenza virus (highly pathogenic) Buelongue virus (Exotic) Bovine spongform encephaloosity agent Camel pox virus Classical swine fever virus Cowdria ruminantium (Heartwake) Foot-and-mouth disease virtus Goat pox virus Japanese encephalitis vitus. Lumpy skin disease virus Malignant catarmal fever virus. (Alorisphine herpesvins type 1) Menangle virus Mycopiasma capricolum/ MUF38/M. mycoldes Capri (contagious caprine pieuroprieumonia) Mycoplasma mycoides mycoldes (contagious bovine pleuropneumonia) Newcastle disease virus (velogenic) Peste des petits rummants virus Rinderpest virus Sheep pox virus Swine vesicular disease virus Vesicular stomattis virus (Exotic)

USDA PLANT PROTECTION AND QUARANTINE (PPQ) SELECT AGENTS AND TOXINS

Candidatus Liberobacter africanus Candidatus Liberobacter asiaticus Percensiderengons philippinesia Rabinos solanacearum race 3, liseval 2 Scherzphirkon rayastare vir a zege Synchytosen endolsoiteum Xanthononias aryase ov. oryasola Xyleia fastikona (otnis weingaled chorpas sham)

2/23/06

USDA, HHS

Category "A" Biological Agents

- Variola major (Smallpox)
- Bacillus anthracis (Anthrax)
- Yersinia pestis (Plague)
- Francisella tularensis (Tularemia)
- Botulinum toxin (Botulism)
- Filoviruses and Arenaviruses (Viral hemorrhagic fevers)

Anthrax-Bacillus anthracis





Cutaneous



Inhalational Usafe.af.mil



Gastrointestinal

Anthrax

- Spore former
- Not transmissible person-person
- Inhalational-high mortality (50-90%)
 2-3 IV antibiotics
- Prophylaxis- ciprofloxacin, doxycycline-60 days

Tularemia



Cutaneous

- •G(-) Coccobacillus
- •1-2 organisms can cause infection
- •Not person-person spread
- •Tx-aminoglycosides, cipro, doxycycline



Botulinum Toxin

- Made by the bacterium Clostridium botulinum
- Most toxic substance on earth food poisoning (0.1 ug lethal dose)
- Weaponizable and aerosolizable (air & food supplies)
- BoTox also used to medically, anti-wrinkle
- Secreted protein neurotoxin causing flaccid paralysis
- Death due to asphyxiation





Image available here: www.stylelist.com/blog/tag/anti-aging/

Cosmetic improvements are NOT bioterrorism

Hemorrhagic Viruses

- Ebola, Marburg, Yellow Fever, Lassa
- Viral syndrome with hemorrhagic complications
- High fatalities with Ebola (80%)
- No treatments, few vaccines (YF)
- Person-person spread



Dr. Lyle Conrad, Joel G. Breman, CDC PHIL #7201



Plague-Yersinia pestis



World Health Organization, CDC PHIL #463



Source Undetermined



CDC PHIL #2047

Bubonic

Septicemic Plague







Source Undetermined PO-INEL

Pneumonic Plague

- Most likely form in BT
- Mortality 80-90%
- Person-person transmission
- Tx- Streptomycin, IV ciprofloxicin or doxycycline
- Prophylaxis- oral cipro or doxy





How would BT agents be disseminated?

• Food

• Water

• Zoonotic

• Aerosol

How would a BT attack be detected?

Clues to a BT Attack

- A large number of ill persons presenting at the same time with a similar disease, especially the following syndromes:
 - o Flaccid paralysis (botulinum toxin)
 - o Hemorrhagic fevers (Ebola, Lassa fever)
 - o Vesicular/pustular rash with considerable mortality (smallpox)
 - o Influenza-like illness associated with a widened mediastinum on chest X-ray and/or meningitis (anthrax)
 - o Pneumonia with painful lymphadenopathy (plague)

Clues to a BT Attack

- Illness in animals and humans concurrently
- A large number of unexplained deaths, especially in young healthy adults
- A single case of an uncommon organism (e.g., smallpox, pulmonary anthrax, Ebola)
- Multiple disease entities presenting in one patient
- An unusual disease presentation (e.g., pneumonic instead of bubonic plague)

Clues to a BT Attack

- An unusual geographic distribution (e.g., Ebola in the U.S.)
- An unusual seasonal pattern (e.g., influenza in summer)
- An illness that fails to respond to usual antimicrobials or vaccines (e.g., engineered antibiotic/vaccine resistant anthrax)
- Clusters of a similar illness in non-contiguous areas, domestic or foreign

36 yo female with rash and fever



Source Undetermined

Smallpox: Overview

- 1980 Global eradication
- Humans were only known reservoir
- Person-to-person transmission (aerosol/ contact)
- Up to 30% mortality in unvaccinated



PO-INEL Source Undetermined

Smallpox: Clinical Features

- Prodrome (incubation 7-17 days)
 - Acute onset of fever, malaise, headache, backache, vomiting, occasional delirium
 - Transient erythematous rash
- Exanthem
 - Begins face, hands, forearms
 - Spread to lower extremities then trunk over ~ 7 days
 - Synchronous progression: macules --> vesicles --> pustules --> scabs
 - Lesions on palms /soles

Smallpox Enanthem



Day 3



World Health Organization

Day 4



World Health Organization





World Health Organization

Day 7







World Health Organization

Day 10-14



World Health Organization





CDC PHIL # 131





	SMALLPOX	CHICKENPOX
FEVER	2–4 days before the rash	At time of rash
RASH Appearance	Pocks at same stage	Pocks in several stages
Development	Slow	Rapid
Distribution	More pocks on arms & legs	More pocks on body
On palms & soles	Usually present	Usually absent
DEATH	More than 10%	Very uncommon

Source Undetermined







World Health Organization

• Smallpox vaccine production using cows



Source Undetermined





Day 4 (8-13-02)



Day 10 (8-19-02)



Day 18 (8-27-02)



Day 6 (8-15-02)



Day 12 (8-21-02)



Day 20 (8-29-02)



Day 8 (8-17-02)



Day 14 (8-23-02)

Normal Reactions

Normal reactions include a wide spectrum of cutaneous presentations:



Staph Infection at Site



Dr. V. Fulginiti

Erythema Multiforme



Dr. V. Fulginiti



Dr. V. Fulginiti



Dr. V. Fulginiti



Arthur E. Kaye CDC ID#:3286



Arthur E. Kaye; J. Michael Lane, M.D. CDC PHIL #3318

Accidental Inoculation



Dr. H. Kempe



Dr. V. Fulginiti



Dr. V. Fulginiti

To sites of acne



Dr. V. Fulginiti

Diaper implantation



Dr. V. Fulginiti

Eczema Vaccinatum



Dr. H. Kempe





Arthur E. Kaye CDC PHIL #3305

Dr. H. Kempe

Generalized Vaccinia







Progressive Vaccinia

Child with Hypogam Child with Hypogam Lymphosarcoma







Child with SCID



Child with SCID



Lymphoma



Vaccinia Keratitis



Dr. V. Fulginiti



Dr. V. Fulginiti

Congenital Vaccinia



Source Undetermined

Source Undetermined

3rd Trimester has the highest risk

Contraindications to Vaccination

- Pregnancy
- Immunodeficiency
- Eczema or Atopic Dermatitis
- Active Skin Conditions
- Active Eye Disease
- Allergy to Components
- Heart Problems

Additional Source Information

for more information see: http://open.umich.edu/wiki/CitationPolicy

Slide 4: Stadium: 1000Faces, Wikimedia Commons, http://commons.wikimedia.org/wiki/File:BigHousePacked.JPG; Airplane: Gautherie, Wikimedia Commons, http://commons.wikimedia.org/wiki/File:Bréquet XIV au décollage La Ferté Alais 1994.jpg Slide 8: Admin-2000, Wikimedia Commons, http://commons.wikimedia.org/wiki/File:40ef87e4e8.jpg, CC:BY-SA 3.0, http://creativecommons.org/licenses/by-sa/3.0/ Slide 9: UCLA Department of Epidemiology, School of Public Health, http://www.ph.ucla.edu/epi/bioter/sverd/sverd fig3.html Slide 13: USDA, HHS, http://www.selectagents.gov/resources/List%20of%20Select%20Agents%20and%20Toxins 111708.pdf Slide 15: U.S. Air Forces in Europe, http://www.usafe.af.mil/direct/sg/anthrax/Pictures/anthrx22.jpg, Sources Undetermined (All other Images) Slide 17: Lesion: Source Undetermined, Thumb: CDC, http://www.cdc.gov/Tularemia/Tul Signssymptoms.html X-Ray: Cornell University Medical College Slide 18: C. botulinum: Source Undetermined; Image of botox injection is available here: www.stylelist.com/blog/tag/anti-aging/ Slide 19: Dr. Lyle Conrad, Joel G. Breman, CDC PHIL #7201; Source Undetermined Slide 20: (From left to right) Source Undetermined; World Health Organization, CDC PHIL #463; CDC PHIL #2047; Source Undetermined Slide 21: Sources Undetermined Slide 22: Source Undetermined Slide 23: 18th century London newspaper Slide 31: Source Undetermined Slide 32: Source Undetermined Slide 35: World Health Organization, http://www.who.int/emc/diseases/smallpox/slideset/ (All images) Slide 36: World Health Organization, http://www.who.int/emc/diseases/smallpox/slideset/ (All images) Slide 37: World Health Organization, http://www.who.int/emc/diseases/smallpox/slideset/ (All images) Slide 38: World Health Organization, http://www.who.int/emc/diseases/smallpox/slideset/ (All images) Slide 39: CDC PHIL # 131, http://emergency.cdc.gov/agent/smallpox/smallpox-images/smallpox1.htm Slide 40: Source Undetermined Slide 41: Source Undetermined Slide 42: World Health Organization, http://www.who.int/emc/diseases/smallpox/slideset/ (All images) Slide 43: Source Undetermined Slide 44: CDC, http://emergency.cdc.gov/training/smallpoxvaccine/reactions/download pocket guide.htm Slide 45: Logical Images (All Images), http://emergency.cdc.gov/training/smallpoxvaccine/reactions/tl_view.htm Slide 46: Source Undetermined Slide 47: Dr. V. Fulginiti Slide 48: Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti; Arthur E. Kaye CDC ID#:3286; Arthur E. Kaye; J. Michael Lane, M.D. CDC PHIL #3318 Slide 49: Dr. H. Kempe; Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti; Slide 50: Dr. H. Kempe; Dr. H. Kempe; Arthur E. Kaye CDC PHIL #3305 Slide 51: Dr. H. Kempe (All Images) Slide 52: Dr. V. Fulginiti (All Images) Slide 53: Dr. V. Fulginiti; Dr. V. Fulginiti Slide 54: Sources Undetermined